FFF

Ford Foundation promotes Anita Khashu and Chi-hui Yang as new program directors

Retrieved on: 
Thursday, February 1, 2024

NEW YORK, Feb. 1, 2024 /PRNewswire/ -- The Ford Foundation announced today the appointments of Anita Khashu as its next program director for Gender, Racial and Ethnic Justice - U.S. (GREJ-U.S.) and Chi-hui Yang as its next program director for Creativity & Free Expression (CFE).

Key Points: 
  • NEW YORK, Feb. 1, 2024 /PRNewswire/ -- The Ford Foundation announced today the appointments of Anita Khashu as its next program director for Gender, Racial and Ethnic Justice - U.S. (GREJ-U.S.) and Chi-hui Yang as its next program director for Creativity & Free Expression (CFE).
  • "Anita Khashu and Chi-hui Yang have been exceptional leaders throughout their respective careers and during their time at the Ford Foundation.
  • "Anita and Chi-hui, alongside the outstanding team we have at Ford, are tasked with the urgent work of reducing inequality and advancing a more just society."
  • Khashu joined the Ford Foundation in 2021 as senior program officer for the foundation's immigrant rights portfolio.

FFF Enterprises Inc. Adds COVID-19 Vaccines and Respiratory Syncytial Virus (RSV) Products to Its Comprehensive, Expanding Portfolio

Retrieved on: 
Wednesday, September 13, 2023

TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with the industry’s top pharmaceutical manufacturers to carry Moderna and Novavax COVID-19 vaccines, ABRYSVO™ and AREXVY RSV vaccines, as well as RSV monoclonal antibody, Beyfortus™ — these products, along with our comprehensive portfolio of influenza vaccines, give healthcare providers the arsenal they need to combat the fast approaching 2023-2024 viral respiratory season.

Key Points: 
  • TEMECULA, Calif., Sept. 13, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, has partnered with the industry’s top pharmaceutical manufacturers to carry Moderna and Novavax COVID-19 vaccines, ABRYSVO™ and AREXVY RSV vaccines, as well as RSV monoclonal antibody, Beyfortus™ — these products, along with our comprehensive portfolio of influenza vaccines, give healthcare providers the arsenal they need to combat the fast approaching 2023-2024 viral respiratory season.
  • “FFF has been a leader in influenza vaccine distribution, so adding a variety of COVID-19 vaccines and RSV products to our portfolio feels instinctive to continue protecting patients and healthcare providers against viral spread, especially as we continue to hear about emerging COVID-19 variants, and we enter respiratory disease season,” said Patrick M. Schmidt, chief executive officer of FFF Enterprises.
  • “We continue to stay true to our mission of Helping Healthcare Care®, which not only includes a commitment to keeping patients safe, but also ensuring medical staff feel protected and equipped.”
    To learn more about FFF Enterprises’ expanding vaccine portfolio, or if you are a medical professional wishing to place an order, visit MyFluVaccine.com .

Feds For Medical Freedom Expands Mission, Announces Rebrand to Feds For Freedom

Retrieved on: 
Friday, September 8, 2023

WASHINGTON, Sept. 8, 2023 /PRNewswire/ -- Feds for Medical Freedom, a group of over 9,000 workers who came together to fight vaccine mandates, has changed its name to "Feds For Freedom" and is expanding its scope and mission.

Key Points: 
  • WASHINGTON, Sept. 8, 2023 /PRNewswire/ -- Feds for Medical Freedom, a group of over 9,000 workers who came together to fight vaccine mandates, has changed its name to "Feds For Freedom" and is expanding its scope and mission.
  • FFF will work to reform the federal service to be more representative of the values of the American people.
  • "Our goal is to ensure that federal workers are truly serving the American people, rather than operating as partisan enforcers."
  • To complement its expanded mission and to serve as a conduit for conversation and debate, Feds For Freedom is also launching a new podcast available on iTunes and other platforms.

FFF Enterprises Announces its Partnership with Verrica Pharmaceuticals to be the Exclusive Distributor of YCANTH™, the First FDA Approved Treatment for Molluscum Contagiosum

Retrieved on: 
Tuesday, August 29, 2023

The U.S. Food and Drug Administration (FDA) describes molluscum contagiosum as “a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated.

Key Points: 
  • The U.S. Food and Drug Administration (FDA) describes molluscum contagiosum as “a viral skin infection that can cause white, pink, or flesh-colored bumps that may itch or become irritated.
  • These bumps can happen alone or in groups almost anywhere on the skin, including the face, neck, arms, legs, stomach, and genital area.
  • The FDA found that YCANTH is a safe and effective topical treatment for patients as young as two years old.
  • “Before the FDA approval of YCANTH, there was a significant unmet need for patients—often children—and their healthcare providers.

Verrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises

Retrieved on: 
Thursday, August 24, 2023

WEST CHESTER, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the first commercial sale of YCANTH™ to its exclusive distributor, FFF Enterprises Inc. (“FFF”).

Key Points: 
  • YCANTH™ is the first and only FDA-approved treatment for molluscum, a highly contagious viral skin infection affecting approximately 6 million people annually in the United States, primarily children
    WEST CHESTER, Pa., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the first commercial sale of YCANTH™ to its exclusive distributor, FFF Enterprises Inc. (“FFF”).
  • “We are pleased to announce the first commercial sale of YCANTH™ to our exclusive distribution partner FFF Enterprises,” said Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals.
  • “As the first FDA-approved product to treat molluscum, YCANTH™ clearly addresses a significant unmet need for the millions of children and adults with this viral skin disease.
  • “With our sales and marketing team fully in place, we are excited to work in partnership with FFF so this large and underserved patient population can benefit from YCANTH™ therapy.”

Premier, Inc. Reports Fiscal-Year 2023 Fourth-Quarter and Full-Year Results

Retrieved on: 
Tuesday, August 22, 2023

* Refer to the supplemental financial information at the end of this release for reconciliation of reported GAAP results to non-GAAP results.

Key Points: 
  • * Refer to the supplemental financial information at the end of this release for reconciliation of reported GAAP results to non-GAAP results.
  • Refer to Supply Chain Services and Performance Services sections below for further discussion on the factors that impacted each segment during the quarter.
  • Adjusted net income of $81.7 million increased 11% from $73.5 million for the same period a year ago.
  • During fiscal 2023, the company paid aggregate dividends of $100.2 million to holders of its Class A common stock.

FFF Enterprises Celebrates 35 Years of Helping Healthcare Care®

Retrieved on: 
Friday, July 7, 2023

TEMECULA, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises, Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, celebrates 12,783 consecutive days (and counting) of supplying healthcare providers and patients with high-quality, counterfeit-free pharmaceuticals.

Key Points: 
  • TEMECULA, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- FFF Enterprises, Inc., recognized as the nation's most trusted specialty drug distributor and diversified healthcare company, celebrates 12,783 consecutive days (and counting) of supplying healthcare providers and patients with high-quality, counterfeit-free pharmaceuticals.
  • “Thirty-five years ago, we started FFF to distribute patient examination gloves.
  • As a leader in the healthcare industry, FFF is constantly expanding and building new manufacturer relationships to provide valuable resources to medical communities.
  • This initiative further underscores FFF’s unwavering commitment to patient care, truly embodying its mission statement: Helping Healthcare Care®.

Kathy Ireland Negotiating with Zoom Casa at Berkshire Hathaway Shareholder's Meeting

Retrieved on: 
Friday, May 5, 2023

OMAHA, Neb., May 5, 2023 /PRNewswire/ -- Kathy Ireland, Chair & CEO of kathy ireland® Worldwide (kiWW®), will attend this year's annual Berkshire Hathaway Shareholder Meeting, beginning today, alongside many marketing and licensing executives.

Key Points: 
  • OMAHA, Neb., May 5, 2023 /PRNewswire/ -- Kathy Ireland, Chair & CEO of kathy ireland® Worldwide (kiWW®), will attend this year's annual Berkshire Hathaway Shareholder Meeting, beginning today, alongside many marketing and licensing executives.
  • Ms. Ireland is a long-term shareholder in Berkshire Hathaway, and a longtime friend of Irv & Susie Blumkin, chair of Nebraska Furniture Mart, and Warren & Astrid Buffet.
  • During the conference, negotiations will continue between kathy ireland® Worldwide and Zoom Casa, a disruptive real estate company led by Fred Bin.
  • Upchurch was instrumental in facilitating multimillion dollar transactions for trusts related to kathy ireland® Worldwide and Zoom Casa.

French football: How Ramadan 2023 reignited the old debate over religion’s place in sport

Retrieved on: 
Tuesday, May 2, 2023

Ramadan came to an end in mid-April, and it was not without controversy in the world of professional football.

Key Points: 
  • Ramadan came to an end in mid-April, and it was not without controversy in the world of professional football.
  • On the other hand, some point to the stellar performances of players like Karim Benzema who claim to observe the fast.
  • Earlier in April, allegations of racism by Paris Saint-Germain’s coach, Christophe Galtier, also added oil to the fire.
  • As academics researching religious expression in the workplace, we find these events typical of contemporary French attitudes.

Religious expression in the workplace: generally peaceful regulation

    • Religious expression in the workplace refers to the demonstration of individuals’ faith in their professional context.
    • Some elements are more diffuse because their religious character is not explicitly mentioned, but they can still be identified as such by colleagues.
    • In spite of France’s culture of secularism, known in French as laïcité, religious expression in the workplace does not tend to stir controversy.

Religion in professional football: nothing new!

    • For many years, including in the French championship, teams have been multicultural, multi-faith, and simply very diverse.
    • This is especially true as players have all the characteristics of what we call “high performers” or “talents”.
    • There are even sports media outlets that create all-star teams based on religion.

A complex phenomenon

    • Different case studies recall some well-known elements in the management of religious practices in the workplace.
    • First, it is important to define a rule, communicate it, ensure it is correctly carried out, and own up to it.
    • Second, the management of religious behaviour at work raises the question of the relationship between common rules and individual rules.
    • Stopping the game for everyone, for example, changes the common rules of the game in favour of an individual religious rule.

Premier, Inc. Reports Fiscal-Year 2023 Third-Quarter Results

Retrieved on: 
Tuesday, May 2, 2023

Refer to Supply Chain Services and Performance Services sections below for further discussion on the factors that impacted each segment during the quarter.

Key Points: 
  • Refer to Supply Chain Services and Performance Services sections below for further discussion on the factors that impacted each segment during the quarter.
  • Adjusted net income of $69.5 million increased 2% from $68.1 million for the same period a year ago.
  • Free cash flow for the nine months ended March 31, 2023 was $199.5 million compared with $201.9 million for the same period a year ago.
  • For the nine months ended March 31, 2023, the company paid aggregate dividends of $75.2 million to holders of its Class A common stock.